Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin plus meropenem versus colistin monotherapy for extensively drug-resistant Pseudomonas aeruginosa bacteremia or pneumonia
2013-005583-25Phase 4Terminated
- Sponsor
- Parc de Salut Mar
- Start
- Jul 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Pseudomonas Sepsis and Pseudomonas pneumonia comparing Colistin + meropenem with Colistin monotherapy (2 arms). Primary endpoint: Clinical and microbiological cure at test of cure. Started Jul 2014; status: terminated.
02
Drugs
colistinmeropenem
03
Conditions
Pseudomonas SepsisPseudomonas pneumonia
Beyond the preview
Go deeper on 2013-005583-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005583-25.